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Abstract
Background: Megalencephalic Leukoencephalopathy with subcortical Cysts (MLC) is a rare type of leukodystrophy
characterized by astrocyte and myelin vacuolization, epilepsy and early-onset macrocephaly. MLC is caused by
mutations in MLC1 or GLIALCAM, coding for two membrane proteins with an unknown function that form a
complex specifically expressed in astrocytes at cell-cell junctions. Recent studies in Mlc1−/− or Glialcam−/− mice and
mlc1−/− zebrafish have shown that MLC1 regulates glial surface levels of GlialCAM in vivo and that GlialCAM is also
required for MLC1 expression and localization at cell-cell junctions.
Methods: We have generated and analysed glialcama−/− zebrafish. We also generated zebrafish glialcama−/−
mlc1−/− and mice double KO for both genes and performed magnetic resonance imaging, histological studies and
biochemical analyses.
Results: glialcama−/− shows megalencephaly and increased fluid accumulation. In both zebrafish and mice, this
phenotype is not aggravated by additional elimination of mlc1. Unlike mice, mlc1 protein expression and
localization are unaltered in glialcama−/− zebrafish, possibly because there is an up-regulation of mlc1 mRNA. In line
with these results, MLC1 overexpressed in Glialcam−/− mouse primary astrocytes is located at cell-cell junctions.
Conclusions: This work indicates that the two proteins involved in the pathogenesis of MLC, GlialCAM and MLC1,
form a functional unit, and thus, that loss-of-function mutations in these genes cause leukodystrophy through a
common pathway.
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Background
One of the most important functions that astrocytes per-
form is buffering the increase in potassium that occurs
during neuronal firing to help restore baseline condi-
tions [1]. Astrocytes buffer excess potassium through
different pathways in a still undefined manner: mainly
via the Na+, K+, ATPase pump, but also using the Na+,
K+, Cl− co-transporter, the potassium channel Kir4.1
and through gap-junction dependent processes [2]. It
has also been suggested that the ClC-2 chloride channel
may play a role in glial potassium accumulation [3, 4].
Animal models deficient in proteins involved in this
process (Kir4.1, ClC-2, Cx32/Cx47, Cx30/Cx43) show
several defects in potassium clearance, increased neur-
onal excitability and presence of vacuoles in myelin [5–
8]. Since water movement is parallel to ion flow, it is
possible that vacuoles are a consequence of an impaired
ion uptake. Additionally, potassium and water entry into
astrocytes also causes cellular swelling. A swelling-
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dependent chloride channel named VRAC (for Volume-
Regulated Anion Channel) strongly expressed in astro-
cytes is then activated, releasing chloride and osmolytes
from the cell, thus changing the driving force for water
movement and restoring the astrocyte’s original size [9].
A similar phenotype to what is present in knockout
animals of genes involved in potassium clearance [5–8]
has been observed in patients affected with Megalence-
phalic Leukoencephalopathy with subcortical Cysts
(MLC), a rare type of leukodystrophy [10]. MLC is char-
acterized by astrocyte and myelin vacuolization, epilepsy
and early-onset macrocephaly [11]. The epilepsy and the
presence of vacuoles in MLC patients suggested a pos-
sible defect in potassium handling [10]. MLC is caused
by mutations in either MLC1 [12] or GLIALCAM [13].
MLC1 encodes for a membrane protein with eight pre-
dicted transmembrane domains (MLC1), which is specif-
ically expressed in astrocytes at cell-cell junctions,
including the Bergmann glia of the cerebellum and
highly enriched in their perivascular endfeet contacting
the blood brain barrier (BBB) [14, 15]. GlialCAM is an
adhesion molecule of the immunoglobulin superfamily
expressed predominantly in astrocytes and oligodendro-
cytes [15, 16].
The pathophysiological mechanisms leading to MLC
are unclear [17]. Apart from the phenotype of MLC pa-
tients, some experimental evidence suggest that Glial-
CAM/MLC1 have a role in potassium clearance: i)
GlialCAM is an auxiliary subunit of the ClC-2 chloride
channel [18]. GlialCAM makes ClC-2 an ohmic channel
due to a change in its gating mechanism [19], which
allow mediating chloride influx at depolarized potentials
[15], as expected for a chloride channel involved in po-
tassium uptake; ii) in astrocyte cultures, localization of
GlialCAM, MLC1 and ClC-2 at cell-cell junctions de-
pend on extracellular potassium [20]; iii) mice models
deficient for Mlc1 or Glialcam display altered brain po-
tassium dynamics [21] and iv) astrocytes deficient in
MLC1 or GlialCAM show reduced VRAC activity [22–
24]. Even though this experimental evidence suggested
the involvement of MLC1 and GlialCAM proteins in po-
tassium uptake, the molecular basis of these defects is
unclear, as the precise functions of MLC1 of GlialCAM
are still unknown.
The biochemical relationships between MLC1 and
GlialCAM are also not well defined. In cultured cell lines
such as HeLa cells, MLC1 cannot reach cell junctions
without GlialCAM, whereas GlialCAM expressed alone
is located at cell-cell junctions [25]. In agreement with
this in vitro data, mice deficient in Glialcam show a mis-
localization of Mlc1 [15, 16]. On the other hand, MLC1
expressed alone in cell lines can reach the plasma mem-
brane [26–28], while in Glialcam knockout mice, Mlc1
is not present at the plasma membrane and Mlc1
protein levels are reduced [15, 16]. Considering that in
primary astrocytes, GlialCAM improves the plasma
membrane localization of MLC-related mutants of
MLC1 that present folding defects, it has been suggested
that GlialCAM has two putative roles: bringing MLC1 at
cell-cell junctions and stabilizing MLC1 [22].
Unexpectedly, both mice [14, 15] and zebrafish [29]
deficient in MLC1 also show a mislocalization of Glial-
CAM in astrocytes and oligodendrocytes. However, this
mislocalization is observed in Bergmann glia [29] but
not in astrocytes surrounding blood vessels [25] in
humans. Furthermore, in astrocyte cultures from
Mlc1−/− mice, GlialCAM is not mislocalized, but it loses
its localization at cell-cell junctions after incubating as-
trocytes with a depolarizing solution [29]. According to
this, it has been suggested that the mislocalization of
GlialCAM when MLC1 is not present depends on the
extracellular potassium concentration by an undefined
mechanism involving signal transduction processes [20,
23, 30, 31].
In summary, although MLC1 and GlialCAM proteins
form a complex located at cell-cell junctions, the bio-
chemical role of each protein in this complex is not well
defined. In the present work, with the aim of under-
standing this relationship, we have generated and ana-
lyzed zebrafish deficient in glialcama as well as zebrafish
and mice deficient in both proteins. Two orthologous
genes for GlialCAM have been described in zebrafish
(glialcama and glialcamb), although previous results
suggested that glialcama is the orthologous gene of
GLIALCAM [29]. The characterization of these models
has provided new insights into the molecular basis of
GlialCAM and MLC1 interactions.
Methods
Zebrafish maintenance
Zebrafish were kept at the animal facility in Bellvitge
Campus, University of Barcelona, under standard condi-
tions at 28 °C, 14 h/10 h light/dark period. AB or AB/TL
strains were used in all the experiments. All experimen-
tal procedures conformed to the European Community
Guidelines on Animal Care and Experimentation and
were approved by animal care and use committees.
Generation of glialcama knockout zebrafish
We designed a pair of TALE nucleases to target two se-
quences at the beginning of glialcama exon1: CTGCTC
TCAAGATGAAGGCA (where the start codon is under-
lined) and TGAAGGAATGGCTGTCTCT, leaving a 20
bp spacer: GAGCGGGAGGCATCATGCAA (BsrBI re-
striction site underlined). Plasmids containing the TALE
nucleases were synthesized by GeneArt (then Life Tech-
nologies), and then cloned by Gateway into pCS2-
destination vector. Plasmids were linearized with KpnI
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and mRNAs were synthesized with mMessage mMa-
chine (Ambion). One hundred pg of each TALE Nucle-
ase mRNA were injected into one cell zebrafish
embryos, DNA was isolated from pooled embryos at
3dpf and the target sequence amplified with the follow-
ing primers: GCCCTGAGTGGACAAATCAT and
AAACTGACAACAGCGCACAC to check if the BsrBI
restriction site was lost due to the action of the TALE
nucleases and the subsequent mistakes made by the cel-
lular repair mechanisms. The remaining embryos were
raised to adulthood and crossed with wild-type animals.
The heterozygosity of their offspring was confirmed by
PCR and High Resolution melting Analysis (HRMA) on
a StepOne PCR machine (Invitrogen). These F1 embryos
were raised to adulthood, tail clipped and genotyped.
PCR products were cloned by TA cloning into the
pGEMt vector (Promega). Individual colonies were se-
quenced using T7 and SP6 primers to characterize the
mutations generated.
Molecular biology
Plasmids used were constructed using standard molecu-
lar biology techniques employing recombinant PCR and
the multisite gateway system (Life Technologies). The
integrity of all cloned constructs was confirmed by DNA
sequencing.
RT-PCR
Adult zebrafish were euthanized using an overdose of
tricaine (MS222, Sigma). Adult tissues were quickly dis-
sected and flash-frozen in liquid nitrogen. Total RNA
was isolated with TRIzol and retrotranscribed using ran-
dom hexamers with the SuperScript IV system (Life
Technologies). The oligonucleotides pairs used for qPCR
are the following: Rpl13a (internal control), sense:
TCTGGAGGACTGTAAGAGGTATGC, anti-sense: TC
TGGAGGACTGTAAGAGGTATGC; mlc1, sense: GCA
CGTTCAGTGGACAACTG, anti-sense: CACAATCAT
TGGGCCTTCAG; glialcama, sense: CCCACCCACC
AAGACTAAGC, anti-sense: CATCCTCAGTCGTGCT
CATCTG; glialcamb, sense: AGACCGGATCTTGG
TGTTTGA, anti-sense: TAGGCTCATCCACAGTGA
GATTGA.
qPCR was performed with SYBR Select reagent (Life
Technologies) in a StepOne apparatus (Life Technolo-
gies). Three experiments were analyzed, with three repli-
cate samples in each experiment. The expression levels
were normalized using the comparative Ct method nor-
malized to the internal control genes. The final results
were expressed as the relative messenger RNA (mRNA)
levels as indicated in the corresponding figures, taking
into account the efficiency of each primer with the Pfaffl
method.
Histological staining methods in zebrafish
Fish were deeply anesthetized in 0.1% tricaine methano-
sulfonate (Sigma, MS-222) in fresh water and fixed by
vascular perfusion with 4% paraformaldehyde in 0.1M
phosphate buffer (PB). Fish heads were post-fixed in the
same fixative for at least 24 h at room temperature.
Next, brains and eyes were extracted, cryopreserved in
30% sucrose in PB, frozen with liquid-nitrogen-cooled
methylbutane and cut in a cryostat. Transverse sections
(12–14 μm thick) were collected onto gelatinized slides.
For immunohistochemistry, sections were rinsed in sa-
line phosphate buffer (PBS) and sequentially incubated
at room temperature with: (1) normal goat serum (NGS,
Sigma, 1:10 in PBS) for 1 h; (2) primary antibody or
cocktail of primary antibodies, overnight (for antibodies
and dilutions, see below); (3) PBS for 15 min; (4) second-
ary fluorescent antibody or cocktail of fluorescent anti-
bodies for 1 h (for antibodies and dilutions, see below);
(6) PBS for 15 min. Incubations with primary and sec-
ondary antibodies were made at room temperature in a
humid chamber. Finally, sections were mounted using
50% glycerol in PB.
Primary antibodies and dilutions used in the study
were: rabbit anti-zebrafish mlc1 (1:100) and rabbit anti-
zebrafish glialcama (1:100). The secondary antibody used
was goat anti rabbit- Alexa Fluor 488 (Invitrogen, 1:500).
All dilutions were done in 10% NGS in PBS. Negative
controls omitting incubation with primary antibody were
performed, showing no unspecific immunoreactivity.
Sections were first observed in a Nikon Eclipse Fluore-
sencent microscope and then selected sections of were
imaged in a Nikon A1R confocal microscope. Confocal
and fluorescent data was processed and analysed using
ImageJ software.
MRI imaging in zebrafish
Magnetic resonance microimaging (μMRI) of Zebrafish
was performed on a vertical wide-bore 7 T Bruker
Avance 300WB spectrometer, with a 1000 mT·m− 1 ac-
tively shielded imaging gradient insert (Bruker Biospin
GmbH, Germany). The system was interfaced to a Linux
PC running Topspin 2.0 and ParaVision 3.2 software
(Bruker Biospin GmbH, Germany). For RF excitation
and detection, a birdcage radio-frequency (RF) coil with
an inner diameter 10 mm was used. For μMRI, adult
zebrafish were euthanized and fixed in 4% buffered para-
formaldehyde (Zinc Formal-Fixx, ThermoShandon, UK)
for 7 days and subsequently embedded in Fomblin (Sol-
vay Solexis, Inc.) to avoid any artefacts that may arise
due to magnetic susceptibility differences at air–tissue
boundaries. The magnetic field homogeneity was opti-
mized by shimming before each μMRI measurement.
For position determination and selection of the desired
region, each session of measurements began with a
Pérez-Rius et al. Orphanet Journal of Rare Diseases          (2019) 14:268 Page 3 of 13
multislice orthogonal gradient-echo sequence. Subse-
quently, high resolution T2 weighted images were ac-
quired by using a rapid acquisition with relaxation
enhancement (RARE) sequences with repetition time
(TR) = 3000 ms; effective echo time (TE) = 18ms; RARE
factor = 4; slice thickness 0.2 mm; field of view 1.2 × 1.2
mm; image matrix of 256 × 256 pixels, resulting in a
spatial resolution of 47 μm.
For transverse relaxation time (T2) measurement, a
standard multi-slice multi-echo (MSME) sequence was
used. This sequence is based on the Carr-Purcell
Meiboom-Gill (CPMG) sequence, where transverse
magnetization of a 90° pulse is refocused by a train of
180° pulses generating a series of echoes. The following
imaging parameters were used: nominal flip angles = 90°
and 180°, and a train of 12 echoes with TEs ranging
from 8.17 ms to 98 ms with 8.17 ms echo-spacing; TR =
2 s, slice thickness 0.5 mm; number of slices 8 and a
matrix size 256 × 256 pixels.
For calculation of T2 relaxation time, regions of inter-
est (ROIs) were drawn at various locations within the
zebrafish brain using an image sequence analysis (ISA)
tool package (Paravision 5, Bruker). Another ROI in the
muscle was used as an internal control. Monoexponen-
tial fitting was then used to calculate T2 using a mono-
exponential fit function [y = A+ C*exp. (−t/T2)], where
A = Absolute bias, C = signal intensity, T2 = transverse
relaxation time. Means and standard deviation for T2 re-
laxation times for each ROI were calculated.
For measurement of brain areas, the desired telence-
phalone and whole brain regions were drawn on the
image and areas were computed using an image se-
quence analysis (ISA) tool package (Paravision 5, Bru-
ker). The data were exported to OriginPro v. 8
(OriginLab, Northampton, MA, USA) for further ana-
lysis and percentage of Telencephalon with respect to
whole brain area was calculated. One-way ANOVA
(Bonferroni’s post-test) for comparison of mean between
each group was performed. Levene’s test was performed
for homogeneity of variance analysis.
Mouse studies
The generation of Glialcam−/− and Mlc1−/− mice has
been previously described [15]. For histological analyses
of brains, mice were perfused with 4% PFA/PBS and or-
gans were postfixed overnight. Haematoxylin–eosin
staining was performed on 6 μm paraffin sections of
brains.
Mouse primary astrocyte cultures were prepared from
cortex and hippocampus, which were removed from
newborn mice. Astrocyte cultures were prepared from 0
to 1 day old OF1 mice. Cerebral cortices were dissected
and the meninges were carefully removed in cold sterile
0.3% BSA, 0.6% glucose in PBS. The tissue was
trypsinized for 10 min at 37 °C and mechanically dissoci-
ated through a small bore fire-polished Pasteur pipette
in complete DMEM medium (Dulbecco’s Modified Ea-
gle’s Medium with 10% heat-inactivated fetal bovine
serum (Biological Industries), 1% penicillin/streptomycin
(Invitrogen) and 1% glutamine (Invitrogen) plus 40 U/ml
DNase I (Sigma)). The cell suspension was pelleted and
re-suspended in fresh complete DMEM, filtered through
a 100-μm nylon membrane (BD Falcon) and plated into
75 cm2 cell culture flasks (TPP). When the mixed glial
cells reached confluence, contaminating microglia, oligo-
dendrocytes and precursor cells were dislodged by
mechanical agitation and removed. Astrocytes were
plated in 6-well plates, at density of 4·105 cells per well,
or in poly-D-lysine-coated cover slips at 7.5·104cells in
24-well plates. Medium was changed every 3 days. In
order to obtain astrocyte cultures arrested in the cell
cycle, medium was replaced and cytosine β-D-
arabinofuranoside (AraC, Sigma) (2 μM) was added. Cul-
tured astrocytes were identified by their positive GFAP
(Glial Fibrillary acid protein) staining (Dako), being >
95% of cells GFAP positive.
For Western blot studies, astrocyte lysates were pre-
pared by homogenization of cells in PBS containing 1%
Triton X-100 and protease inhibitors: 1 μM Pepstatin
and Leupeptin, 1 mM Aprotinin and PMSF, incubated
for 1 h at 4 °C and centrifugated. Supernatants were
quantified using BCA kit (Pierce) and mixed with SDS
loading sample buffer. After SDS PAGE, membranes
were incubated with primary antibodies: anti-MLC1 (1:
100), anti-GlialCAM (1:100) and anti-β-Actin (1:10000,
Sigma) and secondary antibodies: HRP-conjugated anti-
rabbit and anti-mouse (1:10000; Jackson). Quantification
of Western blots was performed by ImageJ at different
exposition times to ensure linearity.
Results
Generation and characterization of zebrafish glialcama
knockout
We previously described that the teleost-specific genome
duplication yielded two glialcam paralogues: glialcama
and glialcamb [29]. Experimental evidence suggests that
glialcama and not glialcamb exerts similar functions to
its orthologue GlialCAM: i) when expressed transiently
in cell lines, glialcama is detected in cell junctions, while
glialcamb is intracellular [29]; ii) glialcama is able to tar-
get MLC1 and ClC-2 to cell junctions in cell lines, but
not glialcamb [29]; iii) glialcama modifies the functional
properties of human and zebrafish ClC-2 proteins
expressed in Xenopus oocytes, whereas glialcamb re-
duces ClC-2 function [32]; iv) it has been shown that in
mlc1−/− glialcama is mislocalized [29], as happens with
GlialCAM in Mlc1−/− mice [15] and v) mlc1 and
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glialcama could be co-immunoprecipitated (Add-
itional file 1: Figure S1).
Using TALEN nucleases (see Methods), we generated
a zebrafish glialcama knockout line that carries a dele-
tion of 7 nucleotides (Δ7) in the first exon of the glial-
cama gene. The deletion changes the open reading
frame after the seventh amino acid and causes a prema-
ture stop codon at amino acid 28 (Fig. 1a). To verify that
this mutation abolished the glialcama protein, we
assayed its expression in brain extracts from wild-type,
heterozygous and homozygous glialcamaΔ7 adult fish
siblings (Fig. 1b). No glialcama protein expression could
be detected in homozygotes, validating glialcamaΔ7 as a
glialcama knockout line (glialcamabcn1), which we will
refer to as glialcama−/− zebrafish from now on. As with
the Glialcam−/− mouse or the mlc1−/− zebrafish [15, 29],
the homozygous glialcama−/− zebrafish turned out to be
viable and fertile, with the expected mendelian ratio
among adult descendants. Previous immunofluorescence
experiments detected similar localization of glialcama
and mlc1 in radial glial cell bodies and their processes in
the brain (Fig. 1c and [29]) and in the retina, where they
are highly expressed at Müller glia end-feet at the inner
limiting membrane (Fig. 1e and [29]). We verified that
the previously observed glialcama localization was spe-
cific, as immunofluorescence studies confirmed no ex-
pression in the glialcama−/− fish neither in the brain nor
in the retina (Fig. 1d and f, respectively).
Comparison of mouse and zebrafish MLC knockout
phenotypes
Histopathology of brain sections from Mlc1−/− and
Glialcam−/− mice revealed the presence of vacuolization
mainly in fibre tracts of the cerebellum [15, 16, 21, 33].
In addition, measurements of brain volume revealed that
the whole brain is bigger in MLC knockout models than
in its wild-type littermates [14, 16, 29]. No major differ-
ences were found in the vacuolization phenotype be-
tween both mice models [15]. Regarding the zebrafish
models, in mlc1−/− animals, MRI showed that the telen-
cephalon is larger in comparison to the wild-type, and
there are several lesions due to increased fluid in the tel-
encephalon and mesencephalon [29].
Therefore, we analysed the brain phenotype of glial-
cama−/− zebrafish by MRI. Furthermore, glialcama−/−
and mlc1−/− zebrafish were pair-wise mated to obtain
animals knockout for both genes or knockout for a sin-
gle gene and heterozygous for the other. Sagittal (Fig. 2a)
and coronal (Fig. 2b) MR images of wild-type and vari-
ous zebrafish mutants were obtained and analysed. We
observed similar lesions in glialcama−/− zebrafish to
what has been previously observed for the mlc1−/− zeb-
rafish [29]. Analysis of T2 relaxation time in the healthy
and damaged brain regions showed similar values for
lesions and the ventricles, indicating that lesions were
due to increased fluid (Additional file 2: Figure S2). Fur-
thermore, as in mlc1−/− animals [29], the size of the tel-
encephalon relative to the whole brain was also larger in
the glialcama−/− (Fig. 2c and Additional file 3: Table S1).
These results indicate that the lack of glialcama causes
two typical MLC features: megalencephaly and increased
fluid accumulation. Furthermore, they also suggest that
glialcamb does not compensate for the lack of glialcama.
For this reason, we did not analyze whether glialcamb
could be co-immunoprecipitated with mlc1 and we did
not generate glialcamb−/− fish.
We further compared the phenotype of the single
knockout zebrafish for one gene with the single knock-
out/heterozygous or the double knockout. No statistical
differences were observed in the percent area of telen-
cephalon after normalizing versus whole brain size nei-
ther in the amount of damaged brain regions (Fig. 2c
and Additional file 3: Table S1).
To study if this was also the case in mice, we analysed
the extent of myelin vacuolization in fibre tracts of the
cerebellum in single or double knockout mice for Mlc1
and Glialcam (Fig. 3). Additional loss of Glialcam in
Mlc1−/−/Glialcam−/− mice did not increase the degree of
vacuolization over that observed for Mlc1−/− or Glial-
cam−/− mice. As previous studies on double knockout
mice for both Clcn2 and Glialcam revealed that incre-
mental effects on vacuolation are readily observed [15],
we conclude that no such incremental effects occurred
in Glialcam / Mlc1 double knockout mice.
Thus, in both animal models (mice and zebrafish) de-
letion of both genes simultaneously did not exacerbate
the brain phenotype of the single knockouts.
Expression and localization of mlc1 is unaltered in
zebrafish glialcama−/−
We then analysed the expression of glialcama, glialcamb
and mlc1 in the brain of glialcama−/− fish by quantitative
real-time PCR (Fig. 4a). We observed that mRNA levels
of glialcama and glialcamb were not changed. In con-
trast, the levels of mlc1 messenger RNA in the brain
were increased in glialcama−/− zebrafish. It is interesting
to point out that no changes in Mlc1 messenger RNA
levels were observed in Glialcam−/− mice [15].
In mice, Mlc1 protein levels are strongly decreased or
absent in Glialcam−/− [15, 16]. We wondered whether
the expression of mlc1 might be also changed in glial-
cama−/− zebrafish. Unexpectedly, mlc1 protein levels
were unchanged in glialcama−/− zebrafish (Fig. 4b).
In mice, ablation of GlialCAM strongly reduced the la-
belling for Mlc1 and changed its localization in Berg-
mann glia and at astrocytic end-feet along blood vessels
[15, 16]. We then studied mlc1 localization in the brain
and retina of wild type and glialcama−/− fish by
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immunofluorescence. We observed no detectable differ-
ences in mlc1 localization between wild type and glial-
cama−/− fish either in the brain (Fig. 4c-d) or in the
retina (Fig. 4e-f).
Mlc1 is mislocalized in primary astrocytes from
Glialcam−/− mice
We wondered whether the differences observed in
MLC1 expression and localization between glialcama−/−
Fig. 1 Generation of a glialcama knockout line in zebrafish. a An allele with a deletion of 7 nucleotides in glialcama (Δ7, from now on −/−) was
generated using a TALEN nuclease. The deletion generates an early stop codon, resulting in a protein of only 28 amino acids in lenght. b
Western blot of brain extracts from adult wild-type (+/+), heterozygous (+/−) or homozygous mutant (−/−) fish for the glialcama knockout allele
demonstrates the absence of the glialcama protein in the homozygous zebrafish. c glialcama expression in the optic tract (Ot) (arrowheads) and
diffusely in cell bodies of the preoptic region (asterisk) of wild type fish (dotted line: optic tract/preoptic region boundary). d No glialcama
immunoreactivity is observed in the optic tract or brain parenchyma of glialcama knockout fish. Dotted line: optic tract/preoptic region boundary.
Asterisk: preoptic region. e glialcama immunoreactivity is observed in the inner limiting membrane of the wild type retina (arrowheads). f No
glialcama immunoreactivity is observed in knockout retina. Expression observed in glialcama−/− represents autofluorescence in photoreceptors
that was consistently observed, even in the case of control immunostainings with secondary antibody only. Arrows point to the inner limiting
membrane. Scale bars: 60 μm (e, f); 75 μm (c, d)
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zebrafish and Glialcam−/− mice could be investigated
in primary astrocyte cultures. In mouse primary astro-
cytes, lack of GlialCAM (Fig. 5a and c) caused a re-
duction of Mlc1 protein, as detected by Western blot
(Fig. 5c) and a mislocalization of Mlc1, as it could
not be detected in astrocyte junctions (Fig. 5b). De-
fects in Mlc1 protein expression and localization were
rescued by expression of human GlialCAM using
adenoviruses that expressed the protein (Fig. 5b and
c). Thus, mouse primary Glialcam−/− cultures
Fig. 2 MR images of wild-type and various zebrafish mutants. a The sagittal slices were obtained with an in-plane resolution of 47 μm. The size of
telencephalon was bigger in mutant zebrafish as compared to wild type (white arrows). Lesions in mesencephalon in mutants are shown with
blue arrows. b The coronal slices were obtained with an in-plane resolution of 47 μm. The size of telencephalon was bigger in mutant zebrafish
as compared to wild type (white arrows). Lesions in telencephalon are shown with blue arrows. c Telencephalon vs. whole brain area (%). In
order to compare the size of the telencephalon relative to the whole brain of the different groups one-way analysis of variance (ANOVA) was
performed and indicated that the size was larger in all mutants as compared to wild type (*p < 0.05; **p < 0.005) (n = 3). No statistical differences
were observed in the percent area of telencephalon versus whole brain size between single knockout zebrafish for one gene with the single
knockout/heterozygous or the double knockout (p > 0.05) (see Additional file 3: Table S1)
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recapitulated the Mlc1 expression defect and
localization observed in vivo.
Zebrafish mlc1 or human MLC1 overexpressed in primary
astrocytes from Glialcam−/− mice are located in cell
junctions
We next investigated in Glialcam−/− mouse primary as-
trocytes what reasons could explain the differences ob-
served between mice and zebrafish regarding MLC1
protein levels and localization. As zebrafish are kept at
28 °C, which is a lower temperature than the
temperature mice are kept (37 °C), we reasoned that
stabilization of MLC1 by GlialCAM might not be neces-
sary at lower temperatures. To test this hypothesis, we
incubated mouse primary astrocytes at 28 °C overnight
and assayed Mlc1 localization (Fig. 6a) and protein levels
(Fig. 6b). However, no changes were observed at lower
temperatures, suggesting that the stabilization of Mlc1
by GlialCAM is not temperature-dependent.
We then reasoned that the zebrafish mlc1 protein
might not need glialcama for its stabilization at the
plasma membrane, unlike their orthologs in mice and
human. To test this hypothesis, we constructed an
adenovirus expressing zebrafish mlc1 and infected Glial-
cam−/− mouse primary astrocytes. Interestingly, zebrafish
mlc1 was located at astrocyte junctions, suggesting that
it may not need Glialcama for targeting to astrocyte
junctions (Fig. 6c). To test that this was not the case for
their human orthologous, we repeated the same experi-
ment now with an adenovirus expressing human MLC1.
Fig. 3 Myelin vacuolization in Glialcam−/−, Mlc1−/− and Glialcam−/−Mlc1−/− mouse models. Haematoxylin-eosin staining of sagittal sections of the
cerebellum of 19- and 61-week-old mice showed similar levels of myelin vacuolization in Glialcam−/−, Mlc1−/− and Glialcam−/−Mlc1−/− animals. As
a control we show the same area of a wild-type mouse at 19 weeks. The inset shows the percentage of vacuolation in double KO animal versus
the vacuolation observed in Glialcam KO animals (n = 3) and Mlc1 KO animals (n = 3) considering each age independently, without substracting
the minor vacuolization observed in wild-type animals. Data were analyzed by GraphPad Prism software. In order to compare the different groups
(dKO vs Glialcam−/− and dKO vs Mlc1−/−), one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni’s multiple comparison test was
used. ns: not significative. Scale bar, 400 μm
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Unexpectedly, human MLC1 overexpressed in Glial-
cam−/− astrocytes was also located at astrocyte junctions
(Fig. 6d).
Discussion
In this work, we have obtained and characterized a glial-
cama knockout in zebrafish. The knockout displays
megalencephaly and fluid accummulation, indicating
that glialcama and not glialcamb, is the functional ortho-
log gene of GlialCAM in zebrafish. We do not know
which could be the role of glialcamb in zebrafish. How-
ever, in vitro studies suggest the possibility that it may
act as a negative regulator of MLC1 and ClC-2 [29, 32].
Taking into account that overexpression of MLC1 has
been reported to be toxic in mice [33], there could be
regulatory mechanisms inhibiting MLC1 function, such
Fig. 4 mlc1 expression and localization in glialcama−/− zebrafish. a Quantitative real-time PCR to determine levels of glialcama, glialcamb and
mlc1 messenger RNA in the brain of glialcama−/− zebrafish. Bars, relative expression levels compared with WT sibling; error bars, s.e. (n ≥ 3). **P <
0.01 (vs. wild-type, two-way ANOVA) b Comparison of mlc1 protein levels in brain of wild-type (WT), mlc1−/−, glialcama−/− and mlc1glialcama−/−
zebrafish by Western blots of extracts from 5-months-old zebrafish. Western blot is representative of three independent experiments. Tubulin
served as a loading control. c, d mlc1 expression (arrowheads) observed in the optic tract of both wild type (c) and glialcama−/− (d) brains. e, f
mlc1 expression is restricted to the inner limiting membrane of the retina (arrowheads) both in wild type (e) and glialcama−/− (f). Scale bars:
50 μm (c, d); 60 μm (e, f)
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as interaction with glialcamb in zebrafish, although ex-
perimental evidence to support this hypothesis is
lacking.
We also show that additional disruption of mlc1 in
glialcama knockout zebrafish or in Glialcam knock-
out mice does not potentiate the vacuolating pheno-
type characteristic of MLC disease, indicating that
loss-of-function mutations in these genes cause leu-
kodystrophy through a common pathway. Previous
[13] and recent [11] reports indicate that the pheno-
type of patients with mutations in MLC1 is the same
to those with recessive mutations in GLIALCAM.
Thus, this genetic evidence in humans, together with
biochemical studies in mice and zebrafish models of
the disease and in vitro studies that indicated Glial-
CAM and MLC1 interaction, indicate that these pro-
teins need to form a complex to carry out their
physiological role. The situation is completely differ-
ent for the ClC-2 protein. First, genetic evidence in-
dicates that defects in MLC1 or CLCN2 lead to
different diseases [34]. Second, the vacuolating
phenotype of Clcn2−/− mice increased after additional
disruption of Glialcam [15]. Thus, we proposed that
defects in ClC-2 might contribute partially to the
MLC phenotype, but it is not the only reason to ex-
plain the phenotype of MLC patients.
Fig. 5 Mlc1 is mislocalized in primary Glialcam−/− astrocytes. Localization of GlialCAM (a) and Mlc1 (b) in primary astrocytes from wild-type (WT,
left), Glialcam−/− (middle) and Glialcam−/− complemented with adenoviruses expressing human GlialCAM (right). In WT and complemented
astrocytes, GlialCAM and Mlc1 are located at cell-cell junctions (arrowheads). Scale bar: 10 μm. (c) GlialCAM and Mlc1 protein levels primary
astrocytes from wild-type (WT, left), Glialcam−/− (middle) and Glialcam−/− complemented with an adenoviruss expressing human GlialCAM. Actin
served as a loading control. Two other independent experiments gave similar results. Densitometric analysis (n = 3) indicates that Mlc1 levels
were reduced in astrocytes from Glialcam−/− mice and expression was recovered after expression of GlialCAM using adenoviruses. * p < 0.05 vs
wild-type astrocytes
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The fact that the MLC1/GlialCAM complex is a
functional unit is evident in the zebrafish knockout
for glialcama, in which mlc1 protein is neither
reduced nor mislocalized but yet it displays an MLC-
like phenotype. In clear contrast, lack of Mlc1 in mice
or mlc1 in zebrafish causes GlialCAM and glialcama
mislocalization, respectively. Surprisingly, this locali
zation defect could only be observed in primary cul-
tured astrocytes from mouse after incubation with a
depolarizing solution [29, 30]. Possibly, the mislocali-
zation of GlialCAM when MLC1 is absent is a conse-
quence of an unknown depolarization-dependent
regulatory mechanism.
We speculate that mlc1 protein levels and localization
in zebrafish are unaltered in the glialcama−/−, because in
the zebrafish knockout there is an up-regulation of mlc1
mRNA, which does not occur in the Glialcam knockout
mice. In agreement with this hypothesis, in primary
Glialcam−/− astrocytes, where endogenous MLC1 is mis-
localized, zebrafish or human MLC1 overexpressed are
located at cell-cell junctions, suggesting that perhaps
MLC1 overexpression compensates for lack of Glial-
CAM stabilizing effect.
Unlike in astrocytes, however, MLC1 overexpressed in
cell lines without GlialCAM is never located at cell-cell
junctions [25]. Possibly, in astrocytes, MLC1 may reach
cell junctions not only by its interaction with GlialCAM,
but also with the help of other proteins that may not be
present in non-astrocyte cell lines.
Conclusions
This work has provided new insights into the molecular
interplay that exists between GlialCAM and MLC1, con-
firming that both proteins form a functional unit that is
physiologically relevant. These results also indicate that
in order to understand the molecular roles performed by
the MLC1/GlialCAM complex, it is important to work
at physiological protein levels, due to the fact that their
overexpression may cause non-physiological effects [33].
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Additional file 1: Figure S1. Co-immunoprecipitation of glialcama and
mlc1 from brain zebrafish. Immunoprecipitation of glialcama from
Fig. 6 zfmlc1 and hMLC1 overexpressed in primary Glialcam−/− astrocytes are located at cell-cell junctions. a, b Primary astrocytes isolated from
Glialcam−/− mice were incubated for 18 h at 28 °C. Then, MLC1 was detected by immunofluoresce (a) and protein levels were monitored by
Western blot (b). Actin served as a loading control. Lack of signal using GlialCAM antibodies confirmed the lack of protein expression. c, d
Overexpression using adenoviruses of mlc1 from zebrafish (zfmlc1, c) and human HA-tagged MLC1 (hMLC1, d) detected both MLC1 proteins at
cell-cell junctions (arrowheads) in primary astrocytes isolated form Glialcam−/− mice. We used antibodies detecting the zebrafish MLC1 or the HA
epitope, which did not detect the endogenous Mlc1. Scale bar: 10 μm
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solubilized brain extracts (Sol) using an anti-glialcama polyclonal antibody
coupled to Sepharose-A beads (IP +). Uncoupled beads were used as a
negative control (IP -). The supernatant (SN) of both purifications is in-
cluded. mlc1 was detected by Western blot. Another experiment gave
similar results.
Additional file 2: Figure S2. T2 relaxation time measurement in the
healthy and various brain regions of wild type, mlc1 KO and mlc1
glialcama dKO mutant zebrafish. Region of interest (ROI) selected for T2
relaxation time measurements are shown in left images. ROI: (1) ventral
telencephalon, (2) lesion in telencephalon, (3) lesion in mesencephalon,
(4) ventricle.
Additional file 3: Table S1. Statistical comparison of wild type and
mutant groups for percentage of area of Telencephalon with respect to
whole brain (related to Fig. 2).
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